| Safety profile of perindopril. | |
| | |
MedLine Citation:
|
PMID: 11591359 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Approximately 25% of US adults have high blood pressure (BP). Selection of effective and safe antihypertensive therapy for these individuals is an important health-care priority. High BP can be treated with a wide range of antihypertensive agents from a number of different classes. These drugs may differ in their suitability for administration to different subpopulations of patients. Results from both clinical trials and postmarketing surveillance indicate that the angiotensin-converting enzyme (ACE) inhibitor perindopril erbumine is safe and well tolerated in a wide range of patients with hypertension. Cough, the most common ACE inhibitor-associated side effect, is also the most common clinical adverse event reported for perindopril, but <2% of perindopril-treated patients discontinue therapy because of cough. Other adverse events often associated with ACE inhibitors, first-dose hypotension and hyperkalemia, appear to occur less often with perindopril than with other agents in this class. The favorable safety profile for perindopril extends to a wide range of patients, including the elderly and those with either heart failure or renal disease. Perindopril has no negative effects on lipids in patients with hyperlipidemia or on glycemic control in patients with type 2 diabetes mellitus, and it reduces proteinuria in patients with renal disease. Perindopril has no known clinically significant drug-drug interactions. Thus, perindopril is a safe BP-lowering agent with documented tolerability in a wide range of patients with hypertension. |
| | |
Authors:
|
L T Clark |
Related Documents
:
|
20847569 - Demographic and clinical characteristics of patients with autosomal dominant polycystic... 9468449 - Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary hea... 21520119 - Idiopathic ulcerative laryngitis. 3020179 - Recent progress on an endogenous digitalislike factor in hypertension. 2142489 - Improved results with surgical treatment of renovascular hypertension: an individualize... 18299649 - Prevalence of gastric varices and portal hypertensive gastropathy in patients with symm... 7809269 - Silicone gel implant explantation: reasons, results, and admonitions. 853549 - Venous thrombosis in acute spinal cord paralysis. 21755119 - Primary progressive aphasia patients evaluated using diffusion tensor imaging and voxel... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: The American journal of cardiology Volume: 88 ISSN: 0002-9149 ISO Abbreviation: Am. J. Cardiol. Publication Date: 2001 Oct |
Date Detail:
|
Created Date: 2001-10-09 Completed Date: 2001-11-01 Revised Date: 2005-11-16 |
Medline Journal Info:
|
Nlm Unique ID: 0207277 Medline TA: Am J Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 36i-40i Citation Subset: AIM; IM |
Affiliation:
|
Department of Medicine, State University of New York Health Science Center at Brooklyn, Brooklyn, New York 11203, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiotensin-Converting Enzyme Inhibitors
/
adverse effects* Humans Hypertension / drug therapy* Perindopril / adverse effects* Product Surveillance, Postmarketing |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 82834-16-0/Perindopril |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effects of perindopril on cardiovascular remodeling.
Next Document: Cellular strategies for proteolytic targeting during migration and invasion.